The prosurvival activity of ascites against TRAIL is associated with a shorter disease-free interval in patients with ovarian cancer

Journal of Ovarian Research

Volumn 3, Issue 1, 2010, Pages

  Lane, Denis ^a   Matte, Isabelle ^a   Rancourt, Claudine ^a   Piche, Alain ^a  

^a UNIVERSITY OF SHERBROOKE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DOXORUBICIN; ETOPOSIDE; NAVELBINE; PACLITAXEL; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ABDOMINAL SURGERY; APOPTOSIS; ARTICLE; ASCITES; CANCER CELL CULTURE; CANCER SURVIVAL; CONTROLLED STUDY; CYTOTOXICITY; DISEASE FREE INTERVAL; FEMALE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; OVARY CANCER; PERITONEAL FLUID; PRIORITY JOURNAL;

EID: 77953388922     PISSN: None     EISSN: 17572215     Source Type: Journal    
DOI: 10.1186/1757-2215-3-1     Document Type: Article

References (33)

1. Cancer statistics, 2008. A Jemal R Siegel E Ward Y Hao J Xu T Murray MJ Thun, CA Cancer J Clin 2008 49 8 31
2. Early events in ovarian epithelial carcinogenesis: progress and problems in experimental approaches. N Auersperg T Ota GW Mitchell, Int J Gynecol Cancer 2002 12 691 703 10.1046/j.1525-1438.2002.01152.x 12445245
3. A putative new growth factor in ascitic fluid from ovarian cancer patients: identification, characterization, and mechanism of action. GB Mills C May M McGill CM Roifman A Mellors, Cancer Res 1988 48 1066 1071 3422589
4. Ascitic fluid from human ovarian cancer patients contains growth factors necessary for intraperitoneal growth of human ovarian adenocarcinoma cells. GB Mills C May M Hill S Campbell P Shaw A Marks, J Clin Invest 1990 86 851 855 10.1172/JCI114784 2394835
5. Characterization of an ovarian cancer activating factor in ascites of ovarian cancer patients. Y Xu DC Gaudette JD Boynton A Frankel XJ Fang A Sharma J Hurteau G Casey A Goodbody A Mellors BJ Holub GB Mills, Clin Cancer Res 1995 1 1223 1232 9815916
6. Identification of interleukin 8 as an inhibitor of tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in the ovarian carcinoma cell line OVCAR3. T Abdollahi NM Robertson A Abdollahi G Litwack, Cancer Res 2003 63 4521 4526 12907626
7. Cytokine level in malignant ascites and peripheral blood of patients with advanced ovarian carcinoma. J Radke D Schmidt M Bohme U Schmidt W Weise J Morenz, Geburtshilfe Frauenheilkd 1996 56 83 87 10.1055/s-2007-1022247 8647364
8. Ascites induces modulation of 61 integrin and urokinase plasminogen activator receptor expression and associated functions in ovarian carcinoma. N Ahmed C Riley K Oliva G Rice M Quinn, Br J Cancer 2005 92 1475 1485 10.1038/sj.bjc.6602495 15798771
9. Characterization of ovarian cancer ascites on cell invasion, proliferation, spheroid formation, and gene expression in an in vitro model of epithelial ovarian cancer. ML Puiffe C Le Page A Filali-Mouhim M Zietarska V Ouellet PN Tonin M Chevrette DM Provencher AM Mes-Masson, Neoplasia 2007 9 820 829 10.1593/neo.07472 17971902
10. Malignant ascites protect against TRAIL-induced apoptosis by activating the PI3K/Akt pathway in human ovarian carcinoma cells. D Lane V Robert R Grondin C Rancourt A Piché Int J Cancer 2007 121 1227 37 10.1002/ijc.22840 17534891
11. Identification and characterization of a new member of the TNF family that induces apoptosis. SR Wiley K Schooley PJ Smolak WS Din CP Huang JK Nicholl GR Sutherland TD Smith C Rauch CA Smith RG Goodwin, Immunity 1995 3 673 682 10.1016/1074-7613(95)90057-8 8777713
12. Cloning and characterization of TRAIL-R3, a novel member of the emerging TRAIL receptor family. MA Degli-Esposti PJ Smolak H Walczak J Waugh CP Huang RF DuBose RG Goodwin CA Smith, J Exp Med 1997 186 1165 1170 10.1084/jem.186.7.1165 9314565
13. TRAIL receptor-2 signals apoptosis through FADD and caspase-8. JL Bodmer N Holler S Reynard P Vinciguerra P Schneider P Juo J Blenis J Tschopp, Nat Cell Biol 2000 2 241 243 10.1038/35008667 10783243
14. A novel receptor for Apo2L/TRAIL contains a truncated death domain. SA Marsters JP Sheridan RM Pitti A Huang M Skubatch V Baldwin J Yuang A Gurney AD Goddard P Godowski A Ashkenazi, Curr Biol 1997 7 1003 1006 10.1016/S0960- 9822(06)00422-2 9382840
15. The novel receptor TRAIL-R4 induces NF-KappaB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain. MA Degli-Esposti WC Dougall PJ Smolak JY Waugh CA Smith RG Goodwin, Immunity 1997 7 813 820 10.1016/S1074-7613(00)80399-4 9430226
16. Cytotoxicity-dependent APO-1 (Fas/CD95)-associated proteins form a death-inducing signaling complex (DISC) with the receptor. FC Kischkel S Hellbardt I Behrmann M Germer M Pawlita PH Krammer ME Peter, EMBO J 1995 14 5579 5588 8521815
17. Differential modulation of apoptosis sensitivity in CD95 type I and type II cells. C Scaffidi I Schmitz J Zha SJ Korsmeyer PH Krammer ME Peter, J Biol Che 1999 274 22532 38 10.1074/jbc.274.32.22532
18. Is TRAIL the holy grail of cancer therapy? T Newsom-Davis S Prieske H Walczak, Apoptosis 2009 14 607 623 10.1007/s10495-009-0321-2 19194800
19. Tumor cell resistance to death receptor-induced apoptosis through mutational inactivation of the proapoptotic Bcl-2 homolog Bax. H LeBlanc D Lawrence E Varfolomeev K Totpal J Morlan P Schow S Fong R Schwall D Sinicropi A Ashkenazi, Nat Med 2002 8 274 81 10.1038/nm0302-274 11875499
20. Differential induction of apoptosis by tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in human ovarian carcinoma cells. D Lane A Cartier S L'Espérance M Cté C Rancourt A Piché Gynecol Oncol 2004 93 594 604 10.1016/j.ygyno.2004.03.029 15196850
21. Mechanisms of resistance to TRAIL-induced apoptosis in cancer. L Zhang B Fang, Cancer Gene Ther 2005 12 228 237 10.1038/sj.cgt.7700792 15550937
22. Comparison of CA-125 and standard definitions of progression of ovarian cancer in the intergroup trial of cisplatin and paclitaxel versus cisplatin and cyclophosphamide. GJ Rustin P Timmers A Nelstrop G Shreeves SM Bentzen B Baron MJ Piccart K Bertelsen G Stuart J Cassidy E Eisenhauer, J Clin Oncol 2006 24 45 51 10.1200/JCO.2005.01.2757 16382112
23. Immunopathologic characterization of a monoclonal antibody that recognizes common surface antigens of human ovarian tumors of serous, endometrioid, and clear cell types. SE Kabawat RC Bast WR Welch RC Knapp RB Colvin, Am J Clin Pathol 1983 79 98 104 6336888
24. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. RC Bast Jr TL Klug E St-John E Jenison JM Niloff H Lazarus RS Berkowitz T Leavitt CT Griffiths L Parker VR Zurawski Jr RC Knapp, N Eng J Med 1983 309 883 887
25. CA125 expression pattern, prognosis and correlation with serum CA125 in ovarian tumor patients from the Danish "MALOVA" Ovarian Cancer Study. EV Hogdall L Christensen SK Kjaer J Blakaer A Kjaerby-Thygesen S Gayther, Gynecol Oncol 2007 104 506 513 10.1016/j.ygyno.2006.09.028
26. Proteomic analysis of malignant ovarian cancer effusions as a tool for biologic and prognostic profiling. B Davidson V Espina SM Steinberg VA Florenes LA Liotta GB Kristensen CG Tropé A Berner EC Kohn, Clin Cancer Res 2006 12 791 799 10.1158/1078-0432.CCR-05-2516 16467090
27. The biology of ovarian cancer: new opportunities for translation. RC Bast Jr B Hennessy GB Mills, Nat Rev Cancer 2009 9 415 428 10.1038/nrc2644 19461667
28. AKT1 amplification regulates cisplatin resistance in human lung cancer cells through the mammalian target of rapamycin/p70S6K1 pathway. L-Z Liu X-D Zhou G Qian X Shi J Fang B-U Jiang, Cancer Res 2007 67 6325 6332 10.1158/0008-5472.CAN-06-4261 17616691
29. Inhibition of phophatidylinositol 3'kinase increases efficacy of paclitaxel in in vitro and in vivo ovarian cancer models. L Hu J Hofmann Y Lu GB Mills RB Jaffe, Cancer Res 2002 62 1087 1092 11861387
30. Ascites from epithelial ovarian cancer contain high levels of functional decoy receptor 3 (DcR3) and is associated with platinum resistance. JP Connor M Felder, Gynecol Oncol 2008 111 330 335 10.1016/j.ygyno.2008.07.012 18723214
31. High expression of tumor necrosis factor-related apoptosis-inducing ligand is associated with favourable ovarian cancer survival. JM Lancaster R Sayer C Blanchette B Calingaert R Whitaker J Schildkraut J Marks A Berchuck, Clin Cancer Res 2003 9 762 766 12576447
32. Expression and function of TNF-related apoptosis-inducing ligand on murine activated NK cells. N Kayagaki N Yamaguchi M Nakayama K Takeda H Akiba H Tsutsui H Okamura K Nakanishi K Okumura H Yagita, J Immunol 1999 163 1906 1913 10438925
33. Expression of TNF-related apoptosis-ligand (TRAIL) and its receptors in gastric carcinoma and tumor-infiltrating lymphocytes: a possible mechanism of immune evasion of the tumor. S Koyama N Koike S Adachi, J Cancer Res Clin Oncol 2002 128 73 79 10.1007/s004320100292 11862476